ResearchMoz

Liver Cancer Therapeutics Market to 2018 - Nexavar, the Only Approved Targeted Therapy for Advanced Disease, Continues to Dominate as Other Late Stage Trials Fail

GBI Research
Published Date » 2012-12-31
No. Of Pages » 72

Liver Cancer Therapeutics Market to 2018 - Nexavar, the Only Approved Targeted Therapy for Advanced Disease, Continues to Dominate as Other Late Stage Trials Fail

Summary

Leading business intelligence provider, GBI Research, has released its latest research report, entitled: “Liver Cancer Therapeutics Market to 2018 - Nexavar, the Only Approved Targeted Therapy for Advanced Disease, Continues to Dominate as Other Late Stage Trials Fail”. The report provides insights into the liver cancer therapeutics market in the US, the top five European countries (the UK, Germany, France, Italy and Spain) and Japan, with market forecasts until 2018. It provides in-depth analysis of the major marketed products, as well as insights into the liver cancer therapeutics R&D pipeline. The report also gives in-depth analysis of the unmet needs, drivers and barriers that affect the markets in these countries. Additionally, it discusses the global pipeline for all the liver cancer molecules across various stages of development. 

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

GBI Research found that the liver cancer therapeutics in the top seven markets (the US, the UK, Germany, France, Spain, Italy and Japan) was estimated at $374.3m in 2011, having grown at a Compound Annual Growth Rate (CAGR) of 21.7% from 2004. Growth was driven by an increase in the patient volume and the Annual Cost of Therapy (ACT) per patient, which increased due to the approval of Nexavar (sorafenib) in the US and Europe. The market is forecast to reach revenues of $644.3m by 2018, growing at a CAGR of 8.1% from 2011.

The current competition in the liver cancer market is weak, as Nexavar is the only drug approved for advanced Hepatocellular Carcinoma (HCC) with the exception of Miripla (miriplatin) in Japan. However, there are some molecules in Phase III development as first-line and second-line treatments which promise to influence the competitive landscape in the next two to three years. The anticipated launch of Eli Lilly's ramucirumab (IMC-1121B), a monoclonal antibody in 2014; Celsion Corporation's ThermoDox in 2014; and PrevOnco in 2015 will drive the market forward.

Scope

  • Annualized market data for the liver cancer therapeutics market from 2004 to 2011 and forecast to 2018
  • Analysis of the liver cancer therapeutics market in the leading geographies of the world: the US, the UK, Germany, France, Italy, Spain, and Japan
  • Market characterization of the liver cancer therapeutics market including market size, annual cost of therapy and treatment usage patterns
  • Key drivers and barriers that affect the market
  • Coverage of pipeline molecules in various Phases of drug development
  • Competitive benchmarking of leading companies including Bayer and Dainippon Sumitomo Pharma
  • Key M&A activities and licensing agreements that have taken place between 2008 and October 2012 in liver cancer therapeutics in the top seven markets

Reasons to buy

  • Align your product portfolio to the markets with high growth potential
  • Develop market-entry and market-expansion strategies by identifying the regions and market segments poised for strong growth
  • Create a more tailored country strategy through the understanding of key drivers and barriers of the liver cancer therapeutics market
  • Develop key strategic initiatives by understanding the key focus areas and top-selling products of leading companies
  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships
Table of Contents

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8

2 Liver Cancer Therapeutics Market to 2018 - Introduction 9

3 Liver Cancer Therapeutics Market to 2018 - Overview 10
3.1 Introduction 10
3.1.1 Benign Tumor 10
3.1.2 Primary Liver Cancer 10
3.1.3 Secondary Liver Cancer 10
3.2 Symptoms 11
3.3 Diagnosis 11
3.3.1 Laboratory Tests 11
3.3.2 Imaging Tests 11
3.3.3 Others 12
3.4 Treatment Options 12
3.4.1 Surgery 13
3.4.2 Non-surgical 13
3.4.3 General Treatment Algorithm 15
3.4.4 Treatment by Stage 16
3.4.5 New Technologies in Treatment 18

4 Liver Cancer Therapeutics Market to 2018 - Market Characterization and Forecasts 19
4.1 Revenue 19
4.2 Annual Cost of Therapy 22
4.3 Marketed Products 23
4.3.1 Nexavar 23
4.3.2 Miripla 25
4.4 Treatment Usage Pattern 27
4.4.1 Prevalence Population 28
4.4.2 Diagnosed Population 28
4.4.3 Prescription Population 28
4.5 Drivers and Barriers of Liver Cancer Therapeutics Market 28
4.5.1 Drivers 28
4.5.2 Barriers 29

5 Liver Cancer Therapeutics Market to 2018 - Geographical Landscape 30
5.1 US 30
5.1.1 Introduction 30
5.1.2 Revenue 30
5.1.3 Cost of Therapy 32
5.1.4 Treatment Usage Pattern 33
5.2 Top Five European Countries 34
5.2.1 Introduction 34
5.2.2 Revenue 34
5.2.3 Cost of Therapy 36
5.2.4 Treatment Usage Pattern 37
5.3 Japan 38
5.3.1 Introduction 38
5.3.2 Revenue 38
5.3.3 Cost of Therapy 39
5.3.4 Treatment Usage Pattern 40

6 Liver Cancer Therapeutics Market to 2018 - Pipeline Analysis 41
6.1 Introduction 41
6.2 R&D Product Pipeline by Stage of Development 43
6.2.1 Phase III 43
6.2.2 Phase II/III 44
6.2.3 Phase II 44
6.2.4 Phase I/II 45
6.2.5 Phase I 46
6.2.6 Pre-Clinical 47
6.2.7 Discovery 47
6.3 Profiles of Promising Molecules 48
6.3.1 PrevOnco 48
6.3.2 Ramucirumab 48
6.3.3 ThermoDox 49
6.3.4 Afinitor 50

7 Liver Cancer Therapeutics Market to 2018 - Competitive Landscape 51
7.1 Bayer 51
7.2 Dainippon Sumitomo Pharma 52

8 Liver Cancer Therapeutics Market to 2018 - Strategic Consolidations 53
8.1 Introduction 53
8.2 Deals by Geography 54
8.3 Deals by Year 55
8.4 Mergers and Acquisition Deals 56
8.4.1 Overview 56
8.4.2 Profiles of Major M&A Deals 57
8.5 Licensing Agreements 58
8.5.1 Overview 58
8.5.2 Profiles of Major Licensing Agreements 60
8.6 Co-Development Agreements 62
8.6.1 Overview 62
8.6.2 Profiles of Major Co-Development Agreements 63

9 Liver Cancer Therapeutics Market to 2018 - Appendix 64
9.1 Market Definitions 64
9.2 Abbreviations 64
9.3 Bibliography 66
9.4 Research Methodology 67
9.4.1 Coverage 67
9.4.2 Secondary Research 68
9.4.3 Primary Research 68
9.5 Therapeutic Landscape 69
9.5.2 Market Size by Geography 70
9.6 Geographical Landscape 71
9.7 Pipeline Analysis 71
9.8 Competitive Landscape 72
9.8.1 Expert Panel Validation 72
9.9 Contact Us 72
9.10 Disclaimer 72

List of Tables


Table 1: Liver Cancer Therapeutics Market, Top Seven Markets, Revenue ($m), 2004-2011 19
Table 2: Liver Cancer Therapeutics Market, Top Seven Markets, Revenue Forecasts ($m), 2011-2018 19
Table 3: Liver Cancer Therapeutics Market, Top Seven Markets, Revenue by Geography ($m), 2004-2011 20
Table 4: Liver Cancer Therapeutics Market, Top Seven Markets, Revenue Forecasts by Geography ($m), 2011-2018 21
Table 5: Liver Cancer Therapeutics Market, Top Seven Markets, Annual Cost of Therapy ($), 2004-2011 22
Table 6: Liver Cancer Therapeutics Market, Top Seven Markets, Annual Cost of Therapy ($), 2011-2018 22
Table 7: Liver Cancer Therapeutics Market to 2018, Nexavar, Clinical Trial Results 23
Table 8: Liver Cancer Therapeutics Market, Nexavar, Adverse Reactions Reported in Clinical Trial 24
Table 9: Liver Cancer Therapeutics Market, Nexavar, Approval History 25
Table 10: Liver Cancer Therapeutics Market, Top Seven Markets, Treatment Usage Pattern (‘000), 2004-2011 27
Table 11: Liver Cancer Therapeutics Market, Top Seven Markets, Treatment Usage Pattern (‘000), 2011-2018 27
Table 12: Liver Cancer Therapeutics Market, US, Revenue ($m), 2004-2011 30
Table 13: Liver Cancer Therapeutics Market, US, Revenue Forecasts ($m), 2011-2018 31
Table 14: Liver Cancer Therapeutics Market, US, Annual Cost of Therapy ($), 2004-2011 32
Table 15: Liver Cancer Therapeutics Market, US, Annual Cost of Therapy ($), 2011-2018 32
Table 16: Liver Cancer Therapeutics Market, US, Treatment Usage Pattern (‘000), 2004-2011 33
Table 17: Liver Cancer Therapeutics Market, US, Treatment Usage Pattern (‘000), 2011-2018 33
Table 18: Liver Cancer Therapeutics Market, Top Five European Countries, Revenue ($m), 2004-2011 35
Table 19: Liver Cancer Therapeutics Market, Top Five European Countries, Revenue Forecast ($m), 2011-2018 35
Table 20: Liver Cancer Therapeutics Market to 2018, Top Five European Countries, Annual Cost of Therapy ($), 2004-2011 36
Table 21: Liver Cancer Therapeutics Market to 2018, Top Five European Countries, Annual Cost of Therapy ($), 2011-2018 36
Table 22: Liver Cancer Therapeutics Market, Top Five European Countries, Treatment Usage Pattern (‘000), 2004-2011 37
Table 23: Liver Cancer Therapeutics Market, Top Five European Countries, Treatment Usage Pattern (‘000), 2011-2018 37
Table 24: Liver Cancer Therapeutics Market, Japan, Revenue ($m), 2004-2011 38
Table 25: Liver Cancer Therapeutics Market, Japan, Revenue Forecast ($m), 2011-2018 39
Table 26: Liver Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2004-2011 39
Table 27: Liver Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2011-2018 39
Table 28: Liver Cancer Therapeutics Market, Japan, Treatment Usage Pattern (‘000), 2004-2011 40
Table 29: Liver Cancer Therapeutics Market, Japan, Treatment Usage Pattern (‘000), 2011-2018 40
Table 30: Liver Cancer Therapeutics Market, Global, Pipeline Products, by Stage of Development, 2012 42
Table 31: Liver Cancer Therapeutics Market, Global, Phase III Pipeline 43
Table 32: Liver Cancer Therapeutics Market, Global, Phase II/III Pipeline 44
Table 33: Liver Cancer Therapeutics Market, Global, Phase II Pipeline 44
Table 34: Liver Cancer Therapeutics Market, Global, Phase I/II Pipeline 45
Table 35: Liver Cancer Therapeutics Market, Global, Phase I Pipeline 46
Table 36: Liver Cancer Therapeutics Market, Global, Preclinical, 2012 47
Table 37: Liver Cancer Therapeutics Market, Global, Discovery, 2012 47
Table 38: Liver Cancer Therapeutics Market, Global, Bayer AG, Pharmaceutical Brands, 2012 51
Table 39: Liver Cancer Therapeutics Market, Global, Dainippon Sumitomo Pharma, Pharmaceutical Brands, 2012 52
Table 40: Liver Cancer Therapeutics Market, Global, Deals by Type of Agreement, 2007-2012 53
Table 41: Liver Cancer Therapeutics Market, Global, Deals by Geography, 2007-2012 54
Table 42: Liver Cancer Therapeutics Market, Global, Deals by Year, 2007-2012 55
Table 43: Liver Cancer Therapeutics Market, Global, Major M&A Deals, 2007-2012 56
Table 44: Liver Cancer Therapeutics Market, Global, Major Licensing Agreement Deals, 2007-2012 58
Table 45: Liver Cancer Therapeutics Market, Global, Major Co-Development Deals, 2007-2012 62

List of Figures


Figure 1: Liver Cancer Therapeutics Market, Global, Hepatocellular Carcinoma, Treatment Options, 2012 12
Figure 2: Liver Cancer Therapeutics Market, Global, Hepatocellular Carcinoma, General Treatment Algorithm 15
Figure 3: Liver Cancer Therapeutics Market, Global, Hepatocellular Carcinoma, Stage I and II, Treatment Algorithm 16
Figure 4: Liver Cancer Therapeutics Market, Global, Hepatocellular Carcinoma, Stage III and IV, Treatment Algorithm 17
Figure 5: Liver Cancer Therapeutics Market, Top Seven Markets, Revenue Forecasts ($m), 2004-2018 19
Figure 6: Liver Cancer Therapeutics Market, Top Seven Markets, Revenue Forecasts by Geography ($m), 2004-2018 20
Figure 7: Liver Cancer Therapeutics Market, Top Seven Markets, Annual Cost of Therapy ($), 2004-2018 22
Figure 8: Liver Cancer Therapeutics Market, Top Seven Markets, Treatment Usage Pattern (‘000), 2004-2018 27
Figure 9: Liver Cancer Therapeutics Market, Top Seven Markets, Drivers and Barriers, 2012 29
Figure 10: Liver Cancer Therapeutics Market, US, Revenue Forecasts ($m), 2004-2018 30
Figure 11: Liver Cancer Therapeutics Market, US, Annual Cost of Therapy ($), 2004-2018 32
Figure 12: Liver Cancer Therapeutics Market, US, Treatment Usage Pattern (‘000), 2004-2018 33
Figure 13: Liver Cancer Therapeutics Market, Top Five European Countries, Revenue Forecast ($m), 2004-2018 34
Figure 14: Liver Cancer Therapeutics Market, Top Five European Countries, Market Revenue ($m), 2004-2018 35
Figure 15: Liver Cancer Therapeutics Market, Top Five European Countries, Annual Cost of Therapy ($), 2004-2018 36
Figure 16: Liver Cancer Therapeutics Market, Top Five European Countries, Treatment Usage Pattern (‘000), 2004-2018 37
Figure 17: Liver Cancer Therapeutics Market, Japan, Revenue Forecast ($m), 2004-2018 38
Figure 18: Liver Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2004-2018 39
Figure 19: Liver Cancer Therapeutics Market, Japan, Treatment Usage Pattern (‘000), 2004-2018 40
Figure 20: Liver Cancer Therapeutics Market, Global, Pipeline Products, by Stage of Development, 2012 41
Figure 21: Liver Cancer Therapeutics Market, Global, Deals by Type of Agreement, 2007-2012 53
Figure 22: Liver Cancer Therapeutics Market, Global, Deals by Geography, 2007-2012 54
Figure 23: Liver Cancer Therapeutics Market, Global, Deals by Year, 2007-2012 55
Figure 24: GBI Research Market Forecasting Model 71

Upcoming Reports:

Chilled And Deli Food Market - Global Industry Size, Market Share, Trends, Analysis, And Forecasts, 2012 - 2018
By - Transparency Market Research
Changing lifestyle and consumer needs are some of the major factors driving chilled and deli food market. This market is gaining traction in developed economies as people are opting for prepared food over fresh foods because of their busy lifestyles. Prepared salads are the fastest growing segment of this industry and pre-packed sandwiches have the highest share in terms of value when compared to any other category in the chilled and deli foods market. Changes in market composition will further decide the overall growth rate of each market segment. One of the biggest...
Life Sciences and Analytical Reagents Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2012 - 2018
By - Transparency Market Research
Life science and analytical reagents are those compounds and substances which are used to detect and create a new substance with the purpose of making them available for test reading and are also known as biotechnology reagents. Such reagents are significant in the areas of research, bioscience, diagnosis and education. This market is driven by factors such as expansion in the use of reagents in the field of therapeutics, growth in research and rapid commercialization of such products. The growth in the field of biotechnology instrumentation also influences the demand for...
Lightweight Materials Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
Lightweight materials and designs have been a crucial element for product designs across several industries which mostly include aviation and automotive industry. Moreover, global trends towards CO2 reduction and resource efficiency have gradually led to an increased demand for light weight materials in the market to manufacture lightweight and fuel efficient vehicles. The lightweight materials that can be commercially used include light metals (magnesium and advanced steel), composites and polymers (carbon fiber) and novel materials (ceramics, carbon nanotubes and others) among others....

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Scientists Identify Cure for Dengue
Apr 18, 2014  
In a breakthrough discovery that can change the way dengue is treated, scientists have identified a drug target for the deadly dengue viruses. This discovery may help pave the way for discovery of vaccines that can cure this condition that affects nearly 390 million people throughout the world each year.  Scientists have used a new technique for this discovery to show that a region...
India is Facing a Cancer Crisis
Apr 15, 2014  
India is currently facing a cancer crisis – reports a recent research carried out at the King’s college London, in collaboration with the Tata Memorial Cancer Centre, Mumbai.  The reasons estimated for this crisis comprise of increasing rates of smoking, unequal access to proper treatment and belated diagnosis.  Every year, India witnesses around one...
Microparticle Tags to Check Counterfeit Goods Invented
Apr 14, 2014  
Researchers from the Massachusetts Institute of Technology have invented a new set of microparticles that can easily be read by smartphones and establish the authenticity of currency, electronic items and luxury goods.  This strategy is among those countless measures taken by big brands and companies to label their legitimate products in order to stop illegal copies of the...
USFDA Approves Lupins Generic Diabetic Drug
Apr 10, 2014  
The United States Food and Drugs Administration (USFDA) has finally approved Lupin Pharmaceuticals Inc (LPI), the American subsidiary of Indian drug manufacturers Lupin Ltd, to sell Pioglitazone Tablets in the U.S market. The approval has been granted first for fiscal 2015.  Pioglitazone is a generic medicine used for managing diabetes and is a version of Actos tablets...
Infrared Sensors can Soon Be Used to Develop Night-Vision Lenses - A New Discovery Confirms
Apr 8, 2014  
People who fear the dark may soon have a reason to rejoice – an infrared sensor that can eventually be used for mechanizing night-vision lenses has been developed. This effectively means that one can also see through dark with the help of these lenses.  This technology seems possible all due to graphene, a layer of tightly packed carbon atoms that has allowed the creation of...